BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19299037)

  • 1. Novel topoisomerase I-targeting antitumor agents synthesized from the N,N,N-trimethylammonium derivative of ARC-111, 5H-2,3-dimethoxy-8,9-methylenedioxy-5-[(2-N,N,N-trimethylammonium)ethyl]dibenzo[c,h][1,6]naphthyridin-6-one iodide.
    Feng W; Satyanarayana M; Tsai YC; Liu AA; Liu LF; LaVoie EJ
    Eur J Med Chem; 2009 Sep; 44(9):3433-8. PubMed ID: 19299037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5-(2-aminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: variation of n-alkyl substituents modulates sensitivity to efflux transporters associated with multidrug resistance.
    Ruchelman AL; Houghton PJ; Zhou N; Liu A; Liu LF; LaVoie EJ
    J Med Chem; 2005 Feb; 48(3):792-804. PubMed ID: 15689163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Facile formation of hydrophilic derivatives of 5H-8,9-dimethoxy-5-[2-(N,N-dimethylamino)ethyl]-2,3-methylenedioxydibenzo[c,h] [1,6]naphthyridin-6-one (ARC-111) and its 12-aza analog via quaternary ammonium intermediates.
    Feng W; Satyanarayana M; Tsai YC; Liu AA; Liu LF; Lavoie EJ
    Bioorg Med Chem Lett; 2008 Jun; 18(12):3570-2. PubMed ID: 18511275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of ARC-111 as a novel topoisomerase I-targeting anticancer drug.
    Li TK; Houghton PJ; Desai SD; Daroui P; Liu AA; Hars ES; Ruchelman AL; LaVoie EJ; Liu LF
    Cancer Res; 2003 Dec; 63(23):8400-7. PubMed ID: 14679002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitro and amino substitution in the D-ring of 5-(2-dimethylaminoethyl)- 2,3-methylenedioxy-5H-dibenzo[c,h][1,6]naphthyridin-6-ones: effect on topoisomerase-I targeting activity and cytotoxicity.
    Singh SK; Ruchelman AL; Li TK; Liu A; Liu LF; LaVoie EJ
    J Med Chem; 2003 May; 46(11):2254-7. PubMed ID: 12747798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity.
    Zhu S; Ruchelman AL; Zhou N; Liu A; Liu LF; LaVoie EJ
    Bioorg Med Chem; 2006 May; 14(9):3131-43. PubMed ID: 16412652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dimethoxybenzo[i]phenanthridine-12-carboxylic acid derivatives and 6H-dibenzo[c,h][2,6]naphthyridin-5-ones with potent topoisomerase I-targeting activity and cytotoxicity.
    Ruchelman AL; Zhu S; Zhou N; Liu A; Liu LF; LaVoie EJ
    Bioorg Med Chem Lett; 2004 Nov; 14(22):5585-9. PubMed ID: 15482929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis of N-substituted 5-[2-(N-alkylamino)ethyl]dibenzo[c,h][1,6]naphthyridines as novel topoisomerase I-targeting antitumor agents.
    Feng W; Satyanarayana M; Cheng L; Liu A; Tsai YC; Liu LF; LaVoie EJ
    Bioorg Med Chem; 2008 Oct; 16(20):9295-301. PubMed ID: 18829334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitro and amino substitution within the A-ring of 5H-8,9-dimethoxy-5-(2-N,N-dimethylaminoethyl)dibenzo[c,h][1,6]naphthyridin-6-ones: influence on topoisomerase I-targeting activity and cytotoxicity.
    Ruchelman AL; Kerrigan JE; Li TK; Zhou N; Liu A; Liu LF; LaVoie EJ
    Bioorg Med Chem; 2004 Jul; 12(13):3731-42. PubMed ID: 15186859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance.
    Antony S; Agama KK; Miao ZH; Takagi K; Wright MH; Robles AI; Varticovski L; Nagarajan M; Morrell A; Cushman M; Pommier Y
    Cancer Res; 2007 Nov; 67(21):10397-405. PubMed ID: 17974983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth inhibitory effect of a new camptothecin analog, DX-8951f, on various drug-resistant sublines including BCRP-mediated camptothecin derivative-resistant variants derived from the human lung cancer cell line PC-6.
    Ishii M; Iwahana M; Mitsui I; Minami M; Imagawa S; Tohgo A; Ejima A
    Anticancer Drugs; 2000 Jun; 11(5):353-62. PubMed ID: 10912951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and biological evaluation of 1,5-naphthyridines as topoisomerase I inhibitors. A new family of antiproliferative agents.
    Alonso C; Fuertes M; González M; Rodríguez-Gascón A; Rubiales G; Palacios F
    Curr Top Med Chem; 2014; 14(23):2722-8. PubMed ID: 25515747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.
    Sooryakumar D; Dexheimer TS; Teicher BA; Pommier Y
    Mol Cancer Ther; 2011 Aug; 10(8):1490-9. PubMed ID: 21636699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of 13H-benzo[f]chromeno[4,3-b][1,7]naphthyridines and their salts as potent cytotoxic agents and topoisomerase I/IIα inhibitors.
    Arepalli SK; Lee C; Sim S; Lee K; Jo H; Jun KY; Kwon Y; Kang JS; Jung JK; Lee H
    Bioorg Med Chem; 2018 Oct; 26(18):5181-5193. PubMed ID: 30253887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP/ABCG2-mediated drug resistance in vitro and in vivo.
    Yamazaki R; Nishiyama Y; Furuta T; Hatano H; Igarashi Y; Asakawa N; Kodaira H; Takahashi H; Aiyama R; Matsuzaki T; Yagi N; Sugimoto Y
    Mol Cancer Ther; 2011 Jul; 10(7):1252-63. PubMed ID: 21566063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the spacer in N,N-bis(alkanol)amine aryl ester heterodimers led to the discovery of a series of highly potent P-glycoprotein-based multidrug resistance (MDR) modulators.
    Dei S; Braconi L; Trezza A; Menicatti M; Contino M; Coronnello M; Chiaramonte N; Manetti D; Perrone MG; Romanelli MN; Udomtanakunchai C; Colabufo NA; Bartolucci G; Spiga O; Salerno M; Teodori E
    Eur J Med Chem; 2019 Jun; 172():71-94. PubMed ID: 30947123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dibenzo[c,h][1,5]naphthyridinediones as topoisomerase I inhibitors: design, synthesis, and biological evaluation.
    Kiselev E; Empey N; Agama K; Pommier Y; Cushman M
    J Org Chem; 2012 Jun; 77(11):5167-72. PubMed ID: 22587603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity and TOP1-targeting activity of 8- and 9-amino derivatives of 5-butyl- and 5-(2-N,N-dimethylamino)ethyl-5H-dibenzo[c,h][1,6]naphthyridin-6-ones.
    Sharma L; Tsai YC; Liu AA; Liu LF; LaVoie EJ
    Eur J Med Chem; 2009 Apr; 44(4):1471-6. PubMed ID: 19012996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of indeno[1,5]naphthyridines as topoisomerase I (TopI) inhibitors with antiproliferative activity.
    Alonso C; Fuertes M; González M; Rubiales G; Tesauro C; Knudsen BR; Palacios F
    Eur J Med Chem; 2016 Jun; 115():179-90. PubMed ID: 27017547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.